Accutane (isotretinoin) was originally investigated for treating skin diseases broadly, including psoriasis, genetic skin disorders, and preventing skin cancer. It was not designed specifically for acne. The drug’s remarkable ability to clear severe cystic acne was discovered during clinical trials in the late 1970s, and that application ultimately became its claim to fame when the FDA approved it in 1982.
How Isotretinoin Went From Lab Curiosity to Skin Research
The story starts in 1969 at the National Cancer Institute, where a dermatology researcher named Gary Peck was looking for a new focus after his original research project fell through. He spent six months in the NIH library and became fascinated by work from Cambridge University showing that vitamin A could fundamentally change how skin cells develop. In lab experiments, adding vitamin A to embryonic chicken skin caused the cells to shift their entire behavior, producing mucus instead of the tough protein (keratin) that skin normally makes. Peck saw potential in this and began studying whether oral retinoids, the class of compounds derived from vitamin A, could treat skin diseases in humans.
Isotretinoin is one of these retinoids. By 1975, Peck contacted the pharmaceutical company Hoffmann-La Roche about testing it across a range of conditions: acne, psoriasis, genetic disorders of the skin, and as a preventive measure against skin cancer. The drug wasn’t being developed with a single purpose in mind. It was a tool for exploring what retinoids could do for diseased skin in general.
The Acne Discovery That Changed Everything
In 1977, Peck launched a four-month clinical trial testing isotretinoin specifically in patients with treatment-resistant acne. The trial was designed as a placebo-controlled, double-blind study, meaning neither the patients nor the researchers were supposed to know who was getting the real drug. That design fell apart almost immediately. Some patients developed severely chapped lips, a telltale sign they were taking the medication rather than the placebo, and the blind was broken at the first four-week follow-up.
Fortunately, the results were already striking by that point. There were statistically significant differences between the drug and placebo groups in just four weeks. Most of the patients on isotretinoin were either cured of their severe acne or experienced long-term remissions even after stopping the drug. That finding, published in the New England Journal of Medicine in 1979, was unusual for an acne treatment. Most acne medications at the time (and many today) only work for as long as you keep using them. Isotretinoin appeared to reset something in the skin that kept acne from coming back.
FDA Approval and Early Warnings
The FDA approved isotretinoin on May 7, 1982, under the brand name Accutane. Its approved use was narrow: severe, recalcitrant, nodular acne in patients who had not responded to conventional therapy, including systemic antibiotics. This was not a first-line acne drug. It was reserved for the worst cases that nothing else could touch.
From the very start, the drug carried serious warnings. The 1982 label noted that isotretinoin could cause birth defects and was classified as a Category X drug, meaning it should never be used during pregnancy. Patients were instructed to use effective contraception while taking it and for one month after stopping. These warnings would grow significantly more elaborate over the following decades as pregnancies continued to occur despite the precautions.
How Safety Monitoring Escalated Over Time
The original 1982 warnings proved insufficient. Babies were being born with severe birth defects linked to isotretinoin exposure, and the FDA pushed for increasingly strict oversight. In the fall of 2001, the agency approved a risk management program called S.M.A.R.T., which took effect by April 2002. Under this system, women of childbearing potential needed two negative pregnancy tests before starting treatment. Doctors had to read an informational booklet about the program, confirm they understood the risks, and place special yellow qualification stickers on prescriptions before pharmacists could fill them.
When S.M.A.R.T. still didn’t reduce pregnancies enough, the FDA approved a third-generation program called iPLEDGE on August 15, 2005. iPLEDGE created a centralized tracking system that touched every link in the supply chain. Only registered wholesalers could obtain isotretinoin from manufacturers. Only registered pharmacies could receive it from wholesalers. Only registered doctors could prescribe it. Female patients of reproductive age had to register separately, log in monthly to answer questions about the program, input their two chosen forms of birth control, and sign a specific informed consent form about birth defects on top of the general consent form all patients signed. Doctors had to enter monthly pregnancy test results and confirm counseling had taken place. iPLEDGE remains in effect today for all isotretinoin products.
What Happened to the Brand Name
Roche eventually stopped marketing Accutane and requested that the FDA withdraw its approval. The formal withdrawal became effective on November 22, 2010. The FDA made clear that this was not a safety or effectiveness issue. Isotretinoin itself continued to be sold under generic versions, which had been available for years. The brand name simply disappeared while the drug lived on.
Cancer Treatment Comes Full Circle
While acne made isotretinoin famous, the drug’s original connection to cancer research never fully went away. Today, isotretinoin is used in the treatment of high-risk neuroblastoma, a cancer that primarily affects young children. In this context, patients take isotretinoin twice daily for 14 days in cycles that repeat every 28 days, for up to six courses. The goal is to use the drug’s ability to change how cells develop and mature, essentially pushing cancer cells toward becoming more normal. This application is closer to what researchers like Peck first envisioned in the 1970s when they were exploring retinoids as a way to modify abnormal cell behavior, well before anyone realized how transformative the drug would be for acne.